CY1106058T1 - Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις - Google Patents

Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις

Info

Publication number
CY1106058T1
CY1106058T1 CY20051101547T CY051101547T CY1106058T1 CY 1106058 T1 CY1106058 T1 CY 1106058T1 CY 20051101547 T CY20051101547 T CY 20051101547T CY 051101547 T CY051101547 T CY 051101547T CY 1106058 T1 CY1106058 T1 CY 1106058T1
Authority
CY
Cyprus
Prior art keywords
lyophilozing
oxapenem
carboxylic acids
pharmaceutical carriers
stable compositions
Prior art date
Application number
CY20051101547T
Other languages
English (en)
Inventor
Hans Rudolf Pfaendler
Original Assignee
Amura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amura Limited filed Critical Amura Limited
Publication of CY1106058T1 publication Critical patent/CY1106058T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Σύμφωνα με την παρούσα εφεύρεση παρέχεται μια φαρμακευτική σύνθεση περιλαμβάνουσα ένα συν-λυοφιλοποίημα από: έναν φαρμακευτικό φορέα˙ και ένα ενεργό συστατικό των τύπων I και II ή ένα φαρμακευτικώς αποδεκτό άλας αυτού, όπου τα R1 και R2, ανεξαρτήτως το ένα από το άλλο, σημαίνουν υδρογόνο, ή φαρμακευτικώς αποδεκτές ομάδες οι οποίες έχουν 1 έως 10 άτομα άνθρακα και συνδέονται στο υπόλοιπο μέρος του μορίου μέσω απλών δεσμών άνθρακα-άνθρακα και όπου τα R3, R4 και R5, ανεξαρτήτως το ένα από το άλλο, σημαίνουν φαρμακευτικώς αποδεκτές ομάδες οι οποίες συνδέονται με το εξωκυκλικό, αλλυλικό άτομο άνθρακα μέσω ατόμων άνθρακα.
CY20051101547T 2000-10-19 2005-12-14 Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις CY1106058T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00309207A EP1199077A1 (en) 2000-10-19 2000-10-19 Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers
PCT/GB2001/004530 WO2002032424A1 (en) 2000-10-19 2001-10-11 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers
EP01974492A EP1326608B1 (en) 2000-10-19 2001-10-11 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers

Publications (1)

Publication Number Publication Date
CY1106058T1 true CY1106058T1 (el) 2011-04-06

Family

ID=8173326

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20051101547T CY1106058T1 (el) 2000-10-19 2005-12-14 Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις

Country Status (12)

Country Link
US (1) US20040043980A1 (el)
EP (2) EP1199077A1 (el)
JP (1) JP2004511520A (el)
AT (1) ATE311881T1 (el)
AU (1) AU2001294007A1 (el)
CY (1) CY1106058T1 (el)
DE (1) DE60115687T2 (el)
DK (1) DK1326608T3 (el)
ES (1) ES2250483T3 (el)
HK (1) HK1053612A1 (el)
WO (1) WO2002032424A1 (el)
ZA (1) ZA200302804B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425314C (en) * 2000-10-19 2009-04-28 Amura Limited Pharmaceutical compositions containing oxapenem-3-carboxylic acids
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition
AR039475A1 (es) * 2002-05-01 2005-02-23 Wyeth Corp 6-alquiliden-penems triciclicos como inhibidores de beta-lactamasa
AR039774A1 (es) * 2002-05-01 2005-03-02 Wyeth Corp 6-alquiliden-penems biciclicos como inhibidores de beta-lactamasas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176349A (en) * 1876-04-18 Improvement in carbureters
US43980A (en) * 1864-08-30 Improvement in horse-rakes
GB2045236A (en) * 1979-03-26 1980-10-29 Hoechst Uk Ltd Oxapenem derivatives
US4293555A (en) * 1979-04-17 1981-10-06 Merck & Co., Inc. 6- and 6,6-Disubstituted-2-substituted-oxapen-2-em-3-carboxylic acids
DE2925009A1 (de) * 1979-06-21 1981-01-08 Basf Ag Zubereitung fuer substanzen, verfahren zu deren herstellung und deren verwendung
DE3725375A1 (de) * 1987-07-31 1989-02-09 Bayer Ag Stabile oxapenem-3-carbonsaeuren
DE3833693A1 (de) * 1988-10-04 1990-04-05 Bayer Ag Stabile oxapenem-3-carbonsaeuren und ihre verwendung als ss-lactamasehemmer
DE4027928A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Neue 2-tert.substituierte methyl-oxapenem-3-carbonsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung
DE4142423A1 (de) * 1991-12-20 1993-06-24 Pfaendler Hans Rudolf ((ls)-hydroxyalkyl)oxapenem-3-carbonsaeuren und ihre verwendung als betalactamasehemmer
NZ285085A (en) * 1994-04-25 1998-04-27 Smithkline Beecham Plc Penem composition, pharmaceutical formulation containing a beta-lactamase inhibiting penem and a beta-lactam antibiotic
AU5985596A (en) * 1995-05-31 1996-12-18 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics

Also Published As

Publication number Publication date
AU2001294007A1 (en) 2002-04-29
ATE311881T1 (de) 2005-12-15
HK1053612A1 (en) 2003-10-31
EP1326608B1 (en) 2005-12-07
DE60115687D1 (de) 2006-01-12
DK1326608T3 (da) 2006-02-06
JP2004511520A (ja) 2004-04-15
EP1326608A1 (en) 2003-07-16
US20040043980A1 (en) 2004-03-04
ZA200302804B (en) 2005-02-23
WO2002032424A1 (en) 2002-04-25
ES2250483T3 (es) 2006-04-16
EP1199077A1 (en) 2002-04-24
DE60115687T2 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
FI964920A (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
ATE295847T1 (de) Aktivsauerstoffaufnehmer enthaltende pterinderivate
DE60014133D1 (de) Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln
CY1106058T1 (el) Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις
FR2771412B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
DE60021286D1 (de) Verfahren zur herstellung von pyrazolo[1,5-b]pyridazin-derivaten
DE69416683T2 (de) Benzolactam-derivate
EP0785190A3 (el)
DE69029781D1 (de) Anthracyclinglycosid-Derivate und Verfahren zu ihrer Herstellung
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
PA8450901A1 (es) Derivados de eritromicina
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
AU2001259242A1 (en) Process for the preparation of chemical compounds
DK455285D0 (da) 2-pyridin-thiolderivater
IL153780A0 (en) Dimethylbenzene derivatives
DK602383A (da) 1,1-diphenylpropanolderivater
GT199800145A (es) 1,3-oxatiolanos sustituidos y 1,3-ditiolanos sustituidos con propiedades antiviricas.
ECSP003488A (es) Derivados de 13- metileritromicina
ECSP992984A (es) Derivados de isotiazol utiles como agentes anticancerosos
ECSP982501A (es) Derivados de eritromicina
KR960030914A (ko) 발모제 조성물
MY106724A (en) Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.